SAT-073 Serum Magnesium, mortality and disease progression in Chronic Kidney disease
Elias Bassil(Cleveland Clinic), Georges Nakhoul(Cleveland Clinic), Evamaria Anvari(Cleveland Clinic), Susana Arrigain(Cleveland Clinic), Jesse D. Schold(Colorado School of Public Health), Rémy Daou(Saint Joseph University), Tushar J. Vachharajani(Cleveland Clinic), Jonathan J. Taliercio(Cleveland Clinic), Joseph V. Nally(Cleveland Clinic), Rami Azem(Cleveland Clinic)
Cited by 0
Related Papers
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
|The Lancet Diabetes & Endocrinology|2019|330
Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data
|Journal of the American Society of Nephrology|2019|209
Masked Hypertension and Elevated Nighttime Blood Pressure in CKD
|Clinical Journal of the American Society of Nephrology|2016|197
Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease
|Clinical Journal of the American Society of Nephrology|2011|181